Deferred Tax Assets, Operating Loss Carryforwards of Immunovant, Inc. from 31 Mar 2019 to 31 Mar 2025

Taxonomy & unit: us-gaap: USD
Description: Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary: Immunovant, Inc. quarterly Deferred Tax Assets, Operating Loss Carryforwards in USD history and change rate from 31 Mar 2019 to 31 Mar 2025.
Immunovant, Inc. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending 31 Mar 2025 was $153,370,000, a 56% increase year-over-year.
Source SEC data: View on sec.gov

Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)

Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Change (%)

Immunovant, Inc. Quarterly Deferred Tax Assets, Operating Loss Carryforwards (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q1 2025	$153,370,000	+$55,122,000	+56%	31 Mar 2025	10-K	29 May 2025	2025	FY
Q1 2024	$98,248,000	+$33,830,000	+53%	31 Mar 2024	10-K	29 May 2025	2025	FY
Q1 2023	$64,418,000	+$24,121,000	+60%	31 Mar 2023	10-K	29 May 2024	2024	FY
Q1 2022	$40,297,000	+$18,432,000	+84%	31 Mar 2022	10-K	22 May 2023	2023	FY
Q1 2021	$21,865,000	+$12,422,000	+132%	31 Mar 2021	10-K	08 Jun 2022	2022	FY
Q1 2020	$9,443,000	+$6,420,000	+212%	31 Mar 2020	10-K	01 Jun 2021	2020	FY
Q1 2019	$3,023,000			31 Mar 2019	10-K	29 Jun 2020	2019	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.